Background: Fibrolamellar hepatocellular carcinoma (FL-HCC) affects children without underlying liver disease. A consistent mutation in FL-HCCs leads to fusion of the genes encoding a heat shock protein (DNAJB1) and the catalytic subunit of protein kinase A (PRKACA). We sought to characterize the resultant chimeric protein and its effects in FL-HCC.
h epatocellular carcinoma (HCC) is one of the most common cancers worldwide, and is the third leading cause of cancer death (1) . Multiple HCC risk factors have been identified, including chronic infection with hepatitis B or C virus, alcoholic cirrhosis, nonalcoholic steatohepatitis, and exposure to aflatoxin (2) . HCC is a genetically heterogeneous disease, as evidenced by these varied risk factors and the resultant underlying cirrhosis that predisposes the liver to carcinogenesis (2) (3) (4) . Fibrolamellar HCC (FL-HCC) is a subtype of HCC that is not only clinically and histologically homogenous, however, but also occurs in children and young adults without underlying liver disease (5, 6) . Histologically, FL-HCCs contain pale, pleomorphic hepatocytes with abundant eosinophilic cytoplasm arranged within a network of lamellar collagen fibers, for which FL-HCC was named.
With recent improvements in whole genome and exome sequencing, there have been significant breakthroughs in our understanding of the molecular pathogenesis of FL-HCC. Honeyman et al. (7) sequenced a series of FL-HCCs and discovered that all tumors in their cohort have a deletion in chromosome 19 , which results in a chimeric transcript that contains the 5' region (exon 1) of the gene-encoding heat shock protein 40 (DNAJB1) fused in-frame to exon 2 of the catalytic (C) subunit of protein kinase A (PRKACA). Tumors express both the chimeric protein (DNAJ-PKA C) and the wild-type (WT) kinase, and the mutation is not found in adjacent normal liver from the same patients, suggesting that it is somatic in nature. Recently, Xu et al. (8) demonstrated that over expression of the chimeric gene enhances proliferation and colony formation in a transformed hepatocyte cell line, supporting its function as an oncogene. Moreover, structural studies have shown that the DNAJ-PKA C fusion protein folds correctly to form a mutant enzyme with all of the hallmarks of an active protein kinase (9) . Several key questions remain, however, including: (i) is this mutation unique to FL-HCC or is it found in other primary liver tumors, (ii) is PKA activity enhanced in FL-HCC compared to nontumor livers, and (iii) does the mutant PKA C subunit have similar enzymatic properties as the WT C subunit? PKA normally exists in the cytoplasm as a holoenzyme composed of two PKA C subunits and two regulatory (R) subunits, of which there are four isoforms (RIα, RIβ, RIIα, RIIβ) (10, 11) . The R subunits function to keep the C subunits inactive in the absence of cyclic adenosine monophosphate (cAMP), and associate with A-kinase anchoring proteins (AKAPs) to constrain localization and function of the enzyme (12, 13) . In the presence of cAMP, C subunits are released from R subunits and are thus able to phosphorylate PKA substrates to direct downstream signaling.
We sought to further characterize the DNAJ-PKA C chimeric protein and components of the PKA holoenzyme in FL-HCCs and paired normal liver samples from our institution. We
We initially sought to determine whether the expression of DNAJB1-PRKACA is unique to FL-HCC. Quantitative realtime polymerase chain reaction (qRT-PCR) was performed on cDNA prepared from four FL-HCCs and paired liver samples, as well as nine "classic" HCCs and two cholangiocarcinomas (CC). Using primers spanning exon 1 of DNAJB1 and exon 3 of PRKACA that specifically detect the mutant transcript, we detected its expression only in FL-HCC samples; not in paired nontumor livers or other primary liver cancers (Figure 1, panel a) . In one case where both a FL-HCC and a focal nodular hyperplasia were resected from the same patient, genomic sequencing using the UW-Oncoplex multiplex gene sequencing panel (14) revealed the chromosome 19 mutation in the FL-HCC, but not in the focal nodular hyperplasia or the patient's nontumor liver. This latter finding was of particular interest, since focal nodular hyperplasias can resemble FL-HCCs on cross-sectional imaging, in that both are characterized as hypervascular lesions with a central scar.
Next, we compared the relative mRNA expression of WT and mutant PRKACA in four FL-HCC tumor samples and paired nontumor livers. PCR was performed using primers that span exons 5-6 of PRKACA. We found that FL-HCC samples express some form of PRKACA at levels 10.6 ± 2.1-fold higher than paired nontumor livers (P = 0.016, Figure 1, panel b) . We also used allele-specific primers to compare the relative expression of WT PRKACA (exons 1-3) and WT DNAJB1 (exons 2-3) with that of DNAJB1-PRKACA (using primers as in Figure 1a ) in FL-HCCs and paired normal livers. Expression levels of WT PRKACA and WT DNAJB1 in tumor samples were equivalent to those of paired, normal livers (Figure 1, panel c) , despite the fact that FL-HCCs only have one WT allele of each of these genes. Further, WT DNAJB1 expression was three-fold higher than WT PRKACA expression, both in FL-HCCs and in paired normal livers. Interestingly, tumor-specific DNAJB1-PRKACA expression was 10.9 ± 1.6-fold higher than WT PRKACA and 3.8 ± 1.1-fold higher than WT DNAJB1. Together, these findings confirm that the mutant transcript is unique to FL-HCC, and that it is expressed at a significantly higher level than either WT PRKACA or WT DNAJB1.
Next, we used immunoblot analyses to determine relative expression of the DNAJB1-PRKACA fusion protein product (DNAJ-PKA C) and WT PKA C in FL-HCC and other primary liver tumors using an antibody directed against the C-terminus of PKA C. Two bands at approximately 46 and 41 kDa are detected in all FL-HCC samples, corresponding to the fusion protein and WT PKA C, respectively (Figure 1,  panel d) . In contrast, only the 41-kDa WT form is detected in the paired, non-tumor livers (N) and in 10 "classic" HCC and 2 CC samples (Figure 1, panel e) . Using densitometry analysis and normalizing to β-actin, we calculated that total PKA C (mutant and WT) protein levels are on average 2.6 ± 0.5-fold higher in FL-HCC samples compared to the WT protein found in paired nontumor livers (Figure 1, panel f) . These findings support our qRT-PCR analyses demonstrating higher PKA C expression in FL-HCCs.
Regulatory Subunit RNA and Protein Expression in Human FL-HCC PKA normally exists as a tetrameric holoenzyme composed of two C and two R subunits (10, 11) ; therefore, it is important to establish whether the DNAJ-PKA C fusion enzyme produced in FL-HCC can interact with the R subunits. We also determined whether R subunit expression levels are differentially regulated in FL-HCC. We found that at the mRNA level, expression levels of PRKARIA are increased 2.0 ± 0. To determine whether DNAJ-PKA C can interact with physiological binding partners in a manner reminiscent of the WT protein, we performed immunoprecipitation in tumor and paired nontumor liver lysates using antibodies to the PKA RIα and PKA RIIα subunits, followed by immunoblotting with antibodies against the C-terminus of PKA C. Immunoblots with antibodies to PKA RIα and PKA RIIα are shown as controls. Figure 3 , panel a shows that both WT and mutant PKA C are present in the immunoprecipitates generated using both PKA R subunit antibodies, indicating that endogenous mutant PKA C can interact with both R subunits. This implies that RI and RII holoenzymes containing the mutant PKA C can form in the tumor cells. Based on relative band intensities, there is a possibility that PKA RIα preferentially binds the mutant PKA C subunit, while PKA RIIα interacts equally with mutant and WT PKA C (Figure 3, panel a) . However, it is difficult to make definitive conclusions about differential binding, as baseline expression levels of the PKA R subunits differ, and factors including cAMP levels and the availability of protein kinase A inhibitor (PKI) and AKAPs may contribute to these binding interactions. Further, after immunoprecipitating with RIα antibody, we did not detect RIIα by immunoblot; nor did we detect RIα in our immunoprecipitates using RIIα antibody ( Figure 3, panel a) . These findings are consistent with a wealth of cell based and structural data showing that each R subunit forms homo dimers through a four helix bundle motif at the extreme amino terminus of each R subunit protomer, precluding the formation of RIα/RIIα heterodimers within a single PKA holoenzyme complex (15) (16) (17) (18) (19) (20) . We performed an additional set of experiments using HEK293 cells that were transiently transfected by YFP-tagged WT and/or mutant PKA C, and confirmed that intact holoenzymes formed with mutant PKA C subunit were able to associate with the anchoring proteins Gravin and AKAP79 (Figure 3, panel b ). Taken together, these studies suggest that the mutant DNAJ-PKA C fusion enzyme behaves like its WT kinase counterpart in terms of its ability to associate with R subunits and AKAPs.
PKA Activity in Human FL-HCC
The ability of the mutant PKA C to interact with PKA R subunits suggests that its kinase activity in FL-HCCs retains its dependency on cAMP, since cyclic nucleotide binding to the R subunits is a key element of PKA holoenzyme activation. To determine PKA activity in these cancers, we performed kinase activity assays using Kemptide as a substrate. These activity measurements were conducted on lysates from FL-HCCs and paired nontumor liver samples (21) . Basal PKA activity (per microgram of protein) does not significantly differ in three of four FL-HCC samples compared to paired normal livers ( Figure 4, panel a) . Yet, in one sample (#4) there is a slight but significant increase in basal PKA activity in the FL-HCC compared to the paired, nontumor liver (0.11 vs. 0.02 pmol/ min/mg, P = 0.01. We then measured PKA activity in the presence of cAMP, which leads to release of C subunits from R subunits and allows PKA to be enzymatically active. We found that three of four FL-HCCs demonstrate a significant increase in cAMP-induced activity compared to the paired nontumor livers ( Total PKA C expression (relative to nontumor liver, normalized to 
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Articles P values all <0.05). Patient number 3 showed less cAMPinduced activity in the FL-HCC compared to its nontumor liver counterpart (0.56 vs. 1.41 pmol/min/mg; Figure 4 , panel a). We then tested the baseline and cAMP-induced PKA activity of three additional FL-HCC samples (two lymph node metastases and one hepatic recurrence) and compared them to the non-tumor liver from a separate patient with FL-HCC. We again found no difference in the baseline PKA activity, but following treatment with cAMP there was an average 3.2-fold increase in PKA activity per microgram of tissue in tumor samples compared to nonpaired liver (Figure 4, panel  b) . Importantly, addition of the PKI 5-24 peptide, a well characterized and specific inhibitor of PKA (22), completely abolished the detected PKA activity in all samples (Supplementary  Figure S1 online).
Next, we performed a dose-response kinase assay using increasing concentrations of cAMP, and confirmed increased cAMP-induced activity in one FL-HCC compared to its paired nontumor liver ( Figure 5, panel a) . While the total enzymatic activity in this FL-HCC was twofold greater than its paired normal liver, the calculated K m for PKA activation are 68.8 ± 22.3 (95% CI: 6.0-130.7) and 36.2 ± 22.04 (95% CI: 0.0-97.4), respectively (P > 0.05) (Figure 5, panel b) . These data suggest that the intrinsic kinase activities are similar in FL-HCC and nontumor liver, and that the increased absolute PKA activities in tumors may thus be attributed to greater enzyme abundance.
Localization of Regulatory and Catalytic Subunits
Upon binding of cAMP to the R subunits, the PKA holoenzyme dissociates in order to permit active C subunit to phosphorylate effector proteins. Moreover, the subcellular location of the PKA holoenzyme is constrained by a family of AKAPs that tether the enzyme in proximity to selected substrates (23) . To determine the subcellular distribution of PKA RIIα and PKA C subunits in FL-HCC, we performed triple immunofluorescent (IF) labeling on formalin-fixed tissues using antibodies to PKA RIIα, PKA C, and 4′,6-diamidino-2-phenylindole (DAPI) (nuclear stain). We found that in both FL-HCCs and normal liver, PKA C and PKA RIIα primarily co-localize in the cytoplasm (Figure 6, panel a) . When we quantified the number of hepatocytes in which there was overlapping PKA C and DAPI signals, suggesting nuclear localization of PKA C, we found that there were "positive" nuclear signals in 3.1 ± 0.7% of tumor cells in FL-HCCs and 3.7 ± 0.4% of hepatocytes in normal livers (Figure 6, panel b) . These data suggest that the mutant PKA C in FL-HCC is predominately localized to the cytoplasm, similar to that of the WT protein.
DISCUSSION
Our findings support the notion that aberrant PKA activity plays a causative role in FL-HCC, and represent the first study to demonstrate enhanced cAMP stimulated PKA activity in human FL-HCC tissues. The oncogenic activity of PKA signaling has been described in human endocrine tumors, including cortisol producing adrenal adenomas and those associated with Carney's syndrome (growth hormone-secreting pituitary adenomas, thyroid, and testicular tumors) (24, 25) . The effects of PKA signaling on cell biology are highly pleiotropic and dependent on cell context and subcellular location (18, 26) . For the most part, PKA inhibits proliferation and promotes differentiated cellular functions, but in certain cells like somatotrophs, PKA activity induces cell division in response to growth hormone. Similarly, inactivation of PRKARIA in GH3 cells, which would enhance PKA activity, stimulates cell proliferation and increases cyclin D1 and ERK activity (27, 28) . We failed to find evidence of elevated ERK phosphorylation in FL-HCCs (Supplementary Figure S2 online ), but instead uncovered consistent mTORC1 activity in these tumors (29) . A relationship between cAMP/PKA signaling and mTORC1 activity has been reported, but these findings have not been consistent and vary with differences in cell lineage (30) . We await the final analyses of a clinical trial evaluating the efficacy of an mTORC1 inhibitor in FL-HCC patients (NCT01642186).
Using a panel of human primary liver tumors, we demonstrate that the DNAJB1-PRKACA chimeric transcript and resultant fusion protein are uniquely and uniformly found in FL-HCCs. How this genomic rearrangement causes hepatocyte transformation in an otherwise normal, noncirrhotic liver remains to be elucidated. Two obvious possibilities include dysregulation of PKA signaling and loss of a DNAJB1 associated function. To begin to address the former hypothesis, previous in vitro work demonstrated that the DNAJB1-PRKACA protein product Articles retains kinase activity, but its activity in human FL-HCCs had not been examined. In this study, we examined a series of FL-HCCs and detected elevated kinase activity in most tumors compared to paired nontumor livers, implying an oncogenic function of the mutant PKA fusion enzyme. Importantly, PKA activity in human FL-HCC is cAMP-dependent, and while the basal activity in tumors is unchanged from that of nontumor liver, FL-HCCs have significantly greater capacity for PKA activation in the presence of cAMP. This finding is consistent with a model in which the mutant PKA C interacts with the R subunits to create a functional holoenzyme that responds to second messengers, but may have different avidity for specific R isoforms. Our in vivo data from patient samples are supported by elegant in vitro studies by Cheung et al. (9) , which were published during the preparation of this manuscript. Their group determined the crystal structure of the DNAJB1-PRKACA protein product, confirmed that it could bind R subunits, and posited that increased PKA activity in FL-HCCs is due to increased expression of C subunit off the DNAJB1 promoter. In keeping with Cheung et al.'s in vitro work, we found elevated PKA activity in FL-HCCs, which could result from a number of causes. Possible explanations include an increase in expression of the fusion transcript beyond that of either WT PRKACA or DNAJB1. Although the 5' promoter sequence of the chimeric gene is in common with WT DNAJB1, the mutant transcript is 3.8-fold more abundant than that of the WT allele. We speculate that loss of the 3' UTR of DNAJB1 in the mutant allele could result in increased mRNA stability. Alternatively, elements within the ~400 kb deletion may influence the promoter activity and transcriptional regulation of DNAJB1-PRKACA. Another possible explanation for the enhanced sensitivity to cAMP in FL-HCCs could be allosteric hindrance by the larger fusion protein, resulting in reduced stability of the heterotetramer in the presence of cAMP. We found that the K m s for activation of PKA in FL-HCC and paired normal liver samples are similar, however, which is supported by in vitro studies showing that intrinsic PKA kinase activity is not altered by the mutation (9). Honeyman et al. similarly reported no difference in the activities of the mutant and WT PKA C when overexpressed in 293 cells (7) . In addition, our data presented in Figure 3b argue that at least in the context of the PKA holoenzymes, the mutant DNAJ-PKA C fusion does not interfere with association with the anchoring proteins Gravin or AKAP79. A logical extension of this finding would be to propose that DNAJ-PKA C fusion is compartmentalized to the membranes and cortical cytoskeleton in FL-HCC tumor cells by virtue of its ability to associate with these AKAPs (31-34). Our notion of normal subcellular distribution of DNAJ-PKA C fusion in FL-HCCs is also consistent with the IF data presented in Figure 6 , which demonstrate that the mutant kinase does not accumulate in the nucleus of tumor cells.
Importantly, we found that increased PKA activity in FL-HCCs is dependent on elevation of intracellular cAMP. This finding suggests that aberrant PKA signaling in FL-HCC would be dependent upon a renewable supply of second messengers. One potential source of increased cAMP is aberrant activation of upstream G-protein coupled receptors (GPCRs) and G proteins such as G αs , which are known to stimulate adenylyl cyclases to increase cAMP synthesis (35) . The neurotensin family of GPCRs is one possible candidate driver; the association between neurotensin and FL-HCC was first demonstrated in 1984, but its molecular significance has not yet been established (36) . Collectively, our results when considered with recent finding from other laboratories extend the argument that the DNAJ-PKA C fusion drives the development of FL-HCC through unknown phosphorylation events in the cytoplasm.
Future investigations of the function of DNAJB1-PRKACA in nontransformed hepatocytes will be critical for enhancing our understanding of the pathogenesis of FL-HCC. The roles of the first exon of DNAJB1 in the context of the fusion transcript and other potential secondary drivers of FL-HCC, such as the CLPTM1L-GLIS3 mutation reported by Xu et al. (8) , also remain to be defined. We anticipate that mapping out the effector pathways downstream of amplified PKA signaling in FL-HCC will lead to the development of targeted therapies for patients with this disease. . After 48 h of expression, cells were lysed using 20 mmol/l Tris-HCl pH8; 30 mmol/l NaCl; 0.02% Triton-X-100; 0.02% Na-DOC; 0.01% SDS; 1 mmol/l EDTA; 1 mmol/l MgCl 2 . Cell lysates were cleared and then incubated with antibodies against Green fluorescent protein (GFP) (A-11122; Life Technologies) overnight. Lysates were incubated with 20 μl Protein G Sepharose beads (Sigma Aldrich) for 1 h, and beads were washed with 1% Triton-X buffer five times. After heating in sample buffer each sample was divided equally and loaded identically on SDS-PAGE gels. Immunoprecipitated samples were immunoblotted with antibodies against AKAP 79 (ABS102, Millipore), Gravin (g3795, Sigma Aldrich), or with the GFP antibody listed above as a control. Primary antibodies were then detected as described above.
Immunofluorescence
Triple-immunofluorescent labeling was performed on formalinfixed normal liver sections using conjugated antibodies to the PKA C subunit (610981, BD Biosciences), PKA RIIα subunit (SC-909, Santa Cruz Biotechnologies), and DAPI (62248, Thermo Scientific), as described (37) . Images were collected on a Zeiss LSM 510 confocal microscope (Carl Zeiss, Oberkochen, Germany). Quantification of PKA C signal in the nucleus was performed using merged images and counting the number of hepatocytes with overlapping green (PKA C) and blue (DAPI) signals. Five hundred total hepatocytes were counted for each sample.
PKA Activity Assay
Tumor and liver lysates were subjected to radioactive kinase activity assays, which were performed in triplicate using Kemptide as a substrate and 32 Pγ-ATP, either with or without incubation with cAMP (5 μmol/l, to maximally stimulate PKA) and/or PKI, a specific inhibitor of PKA as described (21) . Dose-response experiments were performed in triplicate using cAMP concentrations of 30, 100, 300, and 1,000 nmol/l. K m calculations were performed using GraphPad Prism (GraphPad Software, San Diego, CA) and the Michaelis-Menten formula (38) .
Statistical Analyses
Statistical analysis was performed using GraphPad Prism (GraphPad Software) on all data, using the paired Student t-test and analysis of variance with post hoc test where appropriate, with a P value ≤ 0.05 considered to be significant.
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